Palazestrant (OP-1250)
ER+/HER2- metastatic breast cancer (2L+)
Key Facts
About Olema Pharmaceuticals
Olema Pharmaceuticals is pioneering the development of next-generation endocrine therapies for hormone-driven cancers, particularly breast cancer. The company's lead program, palazestrant, is a novel oral CERAN/SERD designed to overcome limitations of current endocrine therapies, including resistance mechanisms. Olema has advanced palazestrant into late-stage clinical development, with a Phase 3 trial (OPERA-01) underway in metastatic breast cancer, positioning the company as a key player in the evolving breast cancer treatment landscape.
View full company profileAbout Olema Pharmaceuticals
Olema Pharmaceuticals is pioneering the development of next-generation endocrine therapies for hormone-driven cancers, particularly breast cancer. The company's lead program, palazestrant, is a novel oral CERAN/SERD designed to overcome limitations of current endocrine therapies, including resistance mechanisms. Olema has advanced palazestrant into late-stage clinical development, with a Phase 3 trial (OPERA-01) underway in metastatic breast cancer, positioning the company as a key player in the evolving breast cancer treatment landscape.
View full company profileAbout Olema Pharmaceuticals
Olema Pharmaceuticals is pioneering the development of next-generation endocrine therapies for hormone-driven cancers, particularly breast cancer. The company's lead program, palazestrant, is a novel oral CERAN/SERD designed to overcome limitations of current endocrine therapies, including resistance mechanisms. Olema has advanced palazestrant into late-stage clinical development, with a Phase 3 trial (OPERA-01) underway in metastatic breast cancer, positioning the company as a key player in the evolving breast cancer treatment landscape.
View full company profileAbout Olema Pharmaceuticals
Olema Pharmaceuticals is pioneering the development of next-generation endocrine therapies for hormone-driven cancers, particularly breast cancer. The company's lead program, palazestrant, is a novel oral CERAN/SERD designed to overcome limitations of current endocrine therapies, including resistance mechanisms. Olema has advanced palazestrant into late-stage clinical development, with a Phase 3 trial (OPERA-01) underway in metastatic breast cancer, positioning the company as a key player in the evolving breast cancer treatment landscape.
View full company profile